Article PDF first page preview

First page of Body Composition and Inflammation as emerging Sex-specific Prognostic Factors in Patients with Advanced Cutaneous Melanoma undergoing Immune Checkpoint-Inhibition Therapy – a Prospective Pilot Study

Introduction The distribution of muscle and adipose tissues masses physiologically follow sex-specific patterns. On the other hand, the clinical and biological consequences of pathologic body composition, i.e. sarcopenia or obesity, also depend on tissue distribution patterns. Although obesity-associated inflammation has been correlated with survival benefits of cancer patients undergoing immune check-point inhibition (ICI) therapy, detailed and sex-specific body composition analyses are widely missing. Here, we prospectively analyzed body composition and serum parameters of inflammation and protein metabolism in patients with advanced melanoma before and three months after initiation of ICI therapy. Methods Between 2016 and 2018 consecutive patients with advanced cutaneous melanoma were recruited into the study at our cancer center (Skin Cancer Center, CIO, University Hospital Cologne, Germany). Blood samples and body composition based on bioelectrical impedance analysis (BIA) were assessed before ICI therapy initiation (T1) and after three months (T2). Correlation of blood parameters with body composition as well as progression-free (PFS) and overall survival (OS) were analyzed in sex-specific subgroups. Results From a total of 54 patients, 25 were women and 29 were men. In women, a high muscle mass at T1 was the strongest marker for longer PFS (HR 0.84; 95-CI 0.74-0.98; p=0.024), while in men (n=29), high phase angle values at T1 correlated with significantly longer PFS (HR 0.48; 95-CI 0.26-0.90; p=0.023). Regarding OS, muscle mass status at T1 remained the strongest predictor for longer survival in women (HR 0.85; 95-CI 0.72-0.99; p=0.033), while in men, increased leukocyte blood counts at T1 were associated with the poorest OS (HR 1.36; 95-CI 1.14-1.62; p=0.001). Inflammation and the immuno-nutritional score mGPS correlated with body composition parameters in a sex-specific manner. However, we did not observe an impact of dynamic changes between T1 and T2 in all analyzed parameters. Conclusion Our data suggest that BIA-derived markers are associated with the prognosis of melanoma patients undergoing ICI therapy in a sex-specific manner. Selected body composition parameters correlate differently with blood markers of inflammation and protein metabolism in men and women. If validated in larger trials, these assessments might improve individualized supportive care and clinical risk stratification.

Journal Section:
Research Article
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.